Is VenomStake a Good Investment?
| TVL | $18M |
| FDV | $402M |
| TVL/FDV | 0.04x |
| Risk Grade | C+ |
| Value Grade | D |
Value Accrual: Does the VenomStake Token Capture Value?
VenomStake scores D on Hindenrank's value accrual framework (22/100), indicating below-average value accrual with significant gaps in fee capture or sustainability. Fee capture scores 4/25 — minimal, with virtually no protocol fees flowing to token holders. Token distribution is rated 8/25 (significantly concentrated among insiders or early investors), and emission sustainability sits at 5/25. The competitive moat dimension scores 5/25.
Protocol Health: Is VenomStake Still Growing?
VenomStake's vitality risk score is 7/10 on Hindenrank's rubric (lower is healthier). This raises concerns about protocol vitality — VenomStake shows signs of declining activity, stagnant or falling TVL, or reduced developer engagement. Investors should monitor whether this trend reverses before increasing exposure.
Risk-Adjusted View: Is the Upside Worth the Risk?
Risk-Adjusted Position
WeakVenomStake falls in the Weak quadrant — moderate risk (C+) with below-average value capture (D). The risk-reward is unfavorable at current levels, as the protocol does not compensate investors adequately for the risks they bear.
Risk Context
VenomStake carries a risk grade of C+ (40/100), classified as elevated risk — multiple novel mechanisms and notable interaction risks. While no critical-severity interactions were identified, 1 high-severity interaction warrant attention. The primary risk factor is: Venom blockchain launched mainnet in March 2024 with under 2 years of production operation, limiting battle-testing of both the chain and the staking protocol
Read our full safety analysis →Should you buy VenomStake?
VenomStake scores D on Hindenrank's value accrual framework, placing it among the below-average Liquid Staking protocols. Fee capture scores 4/25 — minimal, with virtually no protocol fees flowing to token holders. Token distribution is significantly concentrated among insiders or early investors, and emission sustainability sits at 5/25. On the risk side, VenomStake carries a C+ grade (40/100), which is elevated risk — multiple novel mechanisms and notable interaction risks. The combined risk-value position places VenomStake in the Weak quadrant.
VenomStake investment outlook for 2026
With $18M in total value locked and FDV of $402M, giving a TVL/FDV ratio of 0.04, VenomStake's fundamentals do not strongly support the current valuation from a usage perspective. The competitive moat dimension scores 5/25, suggesting limited moat, leaving the protocol vulnerable to competitive pressure.Investors should weigh these fundamentals alongside market conditions and their own risk tolerance.
This analysis is based on cryptoeconomic fundamentals, not price prediction. It is not financial advice. Full methodology
Weekly Commentary
ProWeek of March 3, 2026
VenomStake lands in the Weak quadrant with a D value grade that signals poor fee capture and token economics relative to its risk profile. At $18M TVL on a C+ risk score, this is a small liquid staking operation carrying meaningful risk without compensating holders — bigger, safer alternatives like Lido and Rocket Pool dominate the sector. The risk-reward here is upside-down: you're taking mid-tier risk for bottom-tier value accrual.
Exploring options?
Compare Liquid Staking Alternatives →